mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib-Reference-Cited by-同舟云学术

mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib

Published:2016-10-17 Issue:2 Volume:140 Page:390-399
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Wang Wenjun¹,Bai Wei¹,Wang Enxin¹,Zhao Yan¹,Liu Lei¹,Yang Man¹,Cai Hongwei²,Xia Dongdong¹,Zhang Lei¹,Niu Jing¹,Yin Zhanxin¹,Zhang Zhuoli¹³,Fan Daiming⁴,Xia Jielai⁵,Han Guohong¹

Affiliation:

1. Department of Liver Disease and Digestive Interventional Radiology; Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University; Xi'an China

2. Information Center, School of Stomatology; Fourth Military Medical University; Xi'an China

3. Department of Radiology; Northwestern University; Chicago IL

4. State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases; Xijing Hospital, Fourth Military Medical University; Xi'an China

5. Department of Medical Statistics; Fourth Military Medical University; Xi'an China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference39 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

3. management of hepatocellular carcinoma;EASL-EORTC Clinical Practice Guidelines;J Hepatol,2012

4. TACE and sorafenib: a good marriage?;Abou-Alfa;J Clin Oncol,2011

5. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study;Park;Liver Int,2015

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A single‐institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors;Cancer Medicine;2023-06

2. The Current Situation Regarding TACE-Specific Scores;Transarterial Chemoembolization (TACE);2023

3. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib;Journal of Gastrointestinal Oncology;2022-08

4. ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization;Experimental and Therapeutic Medicine;2021-02-24

5. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma;Digestive Diseases and Sciences;2020-06-17